Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma

Jiménez-Requena, Felisa; Delgado-Bolton, Roberto; Fernández-Pérez, Cristina; Gambhir, Sanjiv S.; Schwimmer, Judy; Pérez-Vázquez, J.M.; Carreras-Delgado, J.L.

doi:10.1007/s00259-009-1224-8

Cited by 90 publications

(73 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ultrasonography associated with Doppler evaluation is of choice in the monitoring of the regional basin, in as much as its sensibility in the detection of occult nodal metastases is approaching 90%; ultrasound utility is now being evaluated by the MSLT-II trial. On the other hand, PET/TC has a diagnostic accuracy superior to that of TC alone in the early detection of visceral metastases whilst its sensitivity in the evaluation of node metastases appears to be lower due to the fact that tumour deposits can be far below its detection threshold [34], [35] and [36]. Another controversial point is the impact of SLN features on OS.…”

Section: Discussionmentioning

confidence: 99%

Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study

Quaglino

Ribero²,

Osella‐Abate

et al. 2011

Surgical Oncology

View full text Add to dashboard Cite

Dec 9. Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for nonsentinel lymph node involvement and overall survival in melanoma patients: a single centre observational cohort study. Quaglino P, Ribero S, Osella-Abate S, Macrì L, Grassi M, Caliendo V, Asioli S, Sapino A, Macripò G, Savoia P, Bernengo MG.You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.(2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy. AbstractObjective: Completion Lymph Node Dissection (CLND) is the current standard of practice for patients with a positive Sentinel Lymph Node Biopsy (SLNB). Significant morbidity is associated to CLND, so we tried to evaluate which prognostic variables could predict NSLN invasion in SLN-positive patients and their impact on the overall survival (OS). Methods: A retrospective chart review of 603 patients that had undergone SLNB for melanoma between 2000 and 2009 at our department was done. 100 SLN were positive at the histopathological analysis of SLN. Demographic variables, primary melanoma, SLN pathologic features and results of CLND were analysed. Multivariate logistic regression and OS analyses were carried out to test the prognostic relevance of clinicopathologic variables on CLND results and disease course. Results: Breslow thickness, ulceration and micro/macrometastatic pattern of SLN invasion carried a significantly independent higher likelihood of NSLN involvement; Starz classification did not maintain a statistical significance in multivariate analysis. Only one patient (4.3%) without adverse prognostic factors showed NSLN involvement, which was found in 33.3% of patients with one and 55.9% with two or more adverse parameters (p = 0.0001). OS analyses confirmed the prognostic significance of these factors. Conclusion: Waiting for the results of Multicenter Selective Lymphadenectomy Trial II, our study suggests a clinically useful and easily applicable means of identifying patients with an unfavourable disease course. The presence of one or more adverse factors identifies patients in whom CLND is mandatory to include thereafter in a more strict follow-up program. Moreover, the finding of no adverse prognostic indicators associated to the presence of significant co-morbidities and/or elderly age, could be useful in identifying patients not to treat by CLND.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study

Quaglino

Ribero²,

Osella‐Abate

et al. 2011

Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…It currently represents the state of the art in PET-based imaging. High-quality studies have shown that the diagnostic significance of PET and PET/CT in melanoma differs depending on tumor stage [104,132,133].…”

Section: S Reskementioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

181

148

View full text Add to dashboard Cite

“…The uptake of FDG is substantially increased in most types of cancers due to the increased metabolism of glucose by tumor cells, as is the case in most lung, colorectal, esophageal, stomach, head and neck, cervical, ovarian, and breast cancers, as well as melanoma and most types of lymphoma [1][2][3]. The utility of FDG in tumor imaging has been fully reviewed [4][5][6][7][8]. However, increased glucose uptake is not a tumor-specific phenomenon; it is also observed in normal cells, such as brain cells, heart cells, and brown fat [9], as well as in infection and inflammation [10].…”

Section: Metabolic Oncologic Tracersmentioning

confidence: 99%

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Zhu

Shim

2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with noninvasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18 F-fluorodeoxyglucose ( 18 F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18 F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18 F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors.

show abstract

Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma

Abstract: FDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease. However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.

Cited by 90 publications

References 42 publications

Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study

Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Contact Info

Product

Resources

About